novel pharmacological applications.

[0004]

Patent Document 1: PCT International Publication No. WO2008/062574

Patent Document 2: Japanese Unexamined Patent Application, Publication No. 2011-68606

SUMMARY OF THE DISCLOSURE

Problems to be solved by the Disclosure

[0005]

In one aspect, there is provided a use of sacran for the manufacture of a medicament for treating or preventing keratoconjunctive disorder.

It is the object of the present disclosure, taking the aforementioned circumstances into consideration, to provide a therapeutic agent and a prophylactic agent for a keratoconjunctive disorder, each agent comprising sacran.

Means for Solving the Problems

[0006]

The present inventors discovered that sacran brings about an excellent improvement effect for corneal disorders in a therapeutic effects test of dry eye and other keratoconjunctive disorders, and completed the present disclsoure.

[0007]

Specifically, the present disclosure provides the following.

[1] A therapeutic agent or a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran.

[2] The therapeutic agent or the prophylactic agent of

CLAIMS

1. Use of sacran for the manufacture of a medicament for treating or preventing keratoconjunctive disorder.

2. The use according to claim 1, wherein the keratoconjunctive disorder is at least one selected from the group consisting of keratitis, conjunctivitis and keratoconjunctivitis.

3. The use according to claim 1, wherein the keratoconjunctive disorder is at least one selected from the group consisting of dry eye, corneal ulcer, corneal erosion, superficial punctate keratopathy, corneal epithelial defect, conjunctival epithelial defect, conjunctive epithelium disorder, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis.

4. The use according to any one of claims 1 to 3 wherein the medicament is in a dosage form of an ophthalmic solution or an ophthalmic ointment.